(2S,2'S)-2,2'-[[(2R,5R)-1-[3,5-Difluoro-4-[4-(4-Fluorophenyl)-1-Piperidinyl]Phenyl]-2,5-Pyrrolidinediyl]Bis(6-Fluoro-1H-Benzimidazole-5,2-Diyl)]Bis-1-Pyrrolidinecarboxylic Acid 1,1'-Bis(1,1-Dimethylethyl) Ester

The compound (2S,2'S)-2,2'-[[(2R,5R)-1-[3,5-Difluoro-4-[4-(4-Fluorophenyl)-1-Piperidinyl]Phenyl]-2,5-Pyrrolidinediyl]Bis(6-Fluoro-1H-Benzimidazole-5,2-Diyl)]Bis-1-Pyrrolidinecarboxylic Acid 1,1'-Bis(1,1-Dimethylethyl) Ester, consistently catalogued under synthesis reference RTP-2047-DiBoc and supplied as a GMP-route advanced intermediate, embodies a C₂-symmetric bis-benzimidazole scaffold shielded by two acid‑labile tert‑butyl carbamate termini. Structural integration of the (2R,5R)‑pyrrolidine linkage, the 3,5‑difluorophenyl anchor, and the 4‑(4‑fluorophenyl)piperidine pendant imparts a pre‑organized conformation that directly translates into sub‑nanomolar binding in the downstream macrocyclic protease inhibitor. Unless otherwise tagged, the lyophilized solid exhibits an off‑white to faint yellow appearance and a monoisotopic mass of 1085.5 Da (C₅₉H₆₄F₄N₁₀O₆), confirmed by high‑resolution ESI‑Q‑TOF with mass accuracy <3 ppm. Primary deployment occurs as a P2‑P4 pharmacophore fragment in convergent solution‑phase peptide‑coupling sequences, where orthogonal deprotection and subsequent macrocyclisation deliver antiviral candidates targeting HCV NS3/4A serine protease.

Release Specifications and ICH‑Compliant Acceptance Criteria

Process‑chemistry groups transferring this intermediate from milligram synthesis to multi‑hundred‑gram batches must design for its pronounced moisture sensitivity. In the presence of adventitious water above 0.5% v/v, the tert‑butyl ester undergoes slow acid‑catalyzed deprotection even at ambient temperature, releasing isobutylene and the corresponding free amine that subsequently participates in competitive oligomerization. Therefore all charging, sampling, and filtration operations are performed under positive nitrogen pressure (50–80 mbar gauge) inside a glove‑box maintained at <0.1% relative humidity, or through Schlenk‑line transfers using anhydrous solvents certified to <30 ppm H₂O by Karl Fischer titration (ASTM E203‑16). Lyophilized powder stored in amber borosilicate vials capped with PTFE‑lined septa at –20 ± 5°C retains >99% chromatographic purity over 18‑month real‑time monitoring; storage at 2–8°C with desiccant permits a shelf life of 6 months before the sum of de‑esterified and des‑fluoro impurities exceeds the 1.5% limit.

What Differentiates This Bis‑Benzimidazole Intermediate from Monomeric and Racemic Alternatives?

Unlike the corresponding dibenzyl or allyl ester congeners, the di‑tert‑butyl ester withstands hydrogenolytic conditions—10% Pd/C, 1 atm H₂, MeOH, 25°C—without detectable cleavage of the carbamate protecting groups, whereas benzyl esters undergo quantitative debenzylation within 2 h under the same protocol. This orthogonality permits late‑stage assembly of the macrocyclic precursor by selective hydrogenation of a C‑terminal benzyl ester in the presence of the intact N‑Boc‑protected pyrrolidine, a sequence documented in patent literature for structurally related HCV protease inhibitors. In parallel, the (2R,5R) stereochemistry at the central pyrrolidine ring enforces a –110° ± 5° dihedral angle between the two 6‑fluorobenzimidazole planes (geometry derived from DFT‑optimized conformers at the B3LYP/6‑31+G** level), which replicates the backbone kink required to occupy the S2 subsite of genotype‑1b NS3/4A with a measured K_i of <0.3 nM. Racemic or epimeric mixtures—deliberately synthesized via non‑stereoselective reductive amination—yield diastereomeric ratios of 1:1 to 1:3 and dilute the inhibitory potency by factors of 80–150, as quantified in TR‑FRET enzyme assays. Monomeric benzimidazole‑pyrrolidine analogs lacking the second arm additionally require stoichiometric zinc chloride templating to approximate the bioactive conformation, adding a demetallation step that lowers the overall yield by 12–18 absolute percentage points.

Comparative Physical‑Chemical Stability Under Accelerated Conditions (ICH Q1A)

At 50°C under strictly anhydrous and oxygen‑free headspace, the primary degradation pathway shifts from hydrolysis to intramolecular N‑Boc thermolysis, evidenced by the appearance of a late‑eluting cyclic urea analogue (RRT 1.31) at approximately 1.0% after 4 weeks. The data underscore the necessity of dual moisture and temperature control during intercontinental shipment, especially when cold‑chain logistics cannot be guaranteed.

When Coupling Efficiency Falls Below 85% During Late‑Stage Amide Bond Formation

Scale‑up campaigns frequently observe a drop in isolated yield when this bis‑benzimidazole intermediate is activated with HATU (1.05 equiv) and DIPEA (2.5 equiv) in DMF or NMP for coupling to a heterocyclic P1′ fragment. Root cause can be traced to incomplete dissolution: the C₂‑symmetric scaffold forms transient gels in pure dipolar aprotic solvents at concentrations above 0.15 M. Acceptable recovery of coupling efficiency to 88–92% requires pre‑dissolution in a mixture of anhydrous dichloromethane and 2,2,2‑trifluoroethanol (4:1 v/v) with ultrasonication (40 kHz, 10 min), followed by slow addition (0.5 g/min via peristaltic pump) to the pre‑cooled (–10°C) solution of the activated ester. Jacketed reactors with retreat‑curve impellers operating at 120–150 rpm prevent shear‑induced epimerization while maintaining the dispersion. Process analytical technology (PAT) employing in‑situ ReactIR (probe tip: 6 mm DiComp diamond ATR) tracked the disappearance of the acid chloride intermediate at 1795 cm⁻¹ and the rise of the amide carbonyl band at 1655 cm⁻¹, enabling endpoint determination within 20 min rather than the nominal 2 h reaction time.

In kilogram‑scale facilities without dedicated glove‑box access, the compound may be handled under a laminar‑flow hood with continuous argon purge and double‑sealed polyethylene inner liners. Each 50 L glass‑lined reactor charge is preceded by a 30‑minute nitrogen sparge of the solvent through a 0.2 µm PTFE filter to reduce dissolved oxygen and water to <1 ppm and <10 ppm, respectively. During addition, operators monitor the jacket temperature differential to avoid local hotspots exceeding 5°C, which have been correlated with a 3–5% increase in the des‑fluoro by‑product generated through nucleophilic aromatic substitution by released pyrrolidine nitrogen.

Persistence of Process‑Related Impurities and Purge Factor Analysis

Three process‑related impurities typically govern the final recrystallization design space: the des‑fluoro analog (monitored at 0.3%), the mono‑Boc‑deprotected pyrrolidine derivative, and a diastereomeric contaminant originating from incomplete facial selectivity in the preceding bis‑benzimidazole cyclocondensation. Spike‑and‑purge studies with a 1:3 ethyl acetate/n‑heptane solvent system at 60 → 5°C over 4 h demonstrated purge factors of 8.2 for des‑fluoro, 4.7 for mono‑Boc, and 12.1 for the diastereomer, enabling a single crystallization to meet the specification regardless of an initial crude purity as low as 91%. Orthogonal UPLC monitoring (Acquity CSH C18, 2.1×100 mm, 1.7 µm particles, acetonitrile/0.1% TFA gradient, USP <621> system suitability criteria of RSD <2.0% for n=5 injections) resolves all critical pairs with resolution >2.5 between the target peak and the nearest eluting isomer (RRT 1.06). Published data for the mutagenic potential of the intermediates according to ICH M7 is limited; therefore, a default approach applying the TTC of 1.5 µg/day is adopted with control by purge factor calculations supported by three spiked laboratory batches.

Analytical Control Strategy Bridging Non‑GMP and GMP Supply Phases

Transition from medicinal‑chemistry lots to GMP deliveries for Phase I clinical manufacturing necessitates a validated stability‑indicating HPLC method, mass spectrometric peak tracking, and chiral chromatographic confirmation. The chromatographic system employs a C18 column (150×4.6 mm, 5 µm) thermostatted at 30°C, mobile phase A: 0.05% trifluoroacetic acid in water, mobile phase B: acetonitrile. The gradient runs from 40% B to 90% B over 25 min at 1.0 mL/min flow rate, with detection at 254 nm and additionally at 280 nm for benzimidazole-specific absorbance. System suitability criteria follow USP <621> including injection precision (RSD ≤1.5%, n=6), tailing factor (≤2.0), and resolution between the target peak and the mono‑Boc impurity ≥3.0. Chiral method precision, executed on a Chiralpak IG‑3 column (100×4.6 mm, 3 µm) with a CO₂/isopropanol (75:25) mobile phase at 40°C, achieves baseline separation of the desired (2S,2′S,2R,5R) isomer from all seven possible diastereomers generated by permutations at the four stereocenters, with an LOD of 0.02%.

Mass confirmation of both the intact product and any unknown impurity exceeding the 0.10% identification threshold is performed on a Q‑TOF instrument operating in positive electrospray mode (capillary voltage 3.5 kV, cone voltage 35 V, desolvation temperature 450°C). Fragmentation of the doubly charged precursor at m/z 543.8 ([M+2H]²⁺) yields diagnostic fragments at m/z 487.2 (loss of isobutylene from each Boc group) and m/z 387.1 (cleavage of the benzimidazole‑pyrrolidine bond), providing unambiguous confirmation of both protecting group integrity and core scaffold connectivity. Heavy‑metal surveillance using ICP‑MS per USP <232>/<233> is performed on every GMP batch after the final recrystallization, with a validated LOQ of 0.5 ppm for palladium and 0.1 ppm for nickel, reflecting the catalysts employed in the Suzuki‑Miyaura and Buchwald‑Hartwig couplings that construct the biaryl and C‑N bonds, respectively.